Literature DB >> 31957467

Long Noncoding RNA Ahit Protects Against Cardiac Hypertrophy Through SUZ12 (Suppressor of Zeste 12 Protein Homolog)-Mediated Downregulation of MEF2A (Myocyte Enhancer Factor 2A).

Junyi Yu1, Yang Yang1, Zaicheng Xu1, Cong Lan1, Caiyu Chen1, Chuanwei Li1, Zhi Chen1, Cheng Yu1, Xuewei Xia1, Qiao Liao1, Pedro A Jose2, Chunyu Zeng1,3, Gengze Wu1.   

Abstract

BACKGROUND: Long noncoding RNA (lncRNA) can regulate various physiological and pathological processes through multiple molecular mechanisms in cis and in trans. However, the role of lncRNAs in cardiac hypertrophy is yet to be fully elucidated.
METHODS: A mouse lncRNA microarray was used to identify differentially expressed lncRNAs in the mouse hearts following transverse aortic constriction-induced pressure overload comparing to the sham-operated samples. The direct impact of one lncRNA, Ahit, on cardiomyocyte hypertrophy was characterized in neonatal rat cardiomyocytes in response to phenylephrine by targeted knockdown and overexpression. The in vivo function of Ahit was analyzed in mouse hearts by using cardiac-specific adeno-associated virus, serotype 9-short hairpin RNA to knockdown Ahit in combination with transverse aortic constriction. Using catRAPID program, an interaction between Ahit and SUZ12 (suppressor of zeste 12 protein homolog) was predicted and validated by RNA immunoprecipitation and immunoblotting following RNA pull-down. Chromatin immunoprecipitation was performed to determine SUZ12 or H3K27me3 occupancy on the MEF2A (myocyte enhancer factor 2A) promoter. Finally, the expression of human Ahit (leukemia-associated noncoding IGF1R activator RNA 1 [LUNAR1]) in the serum samples from patients of hypertrophic cardiomyopathy was tested by quantitative real-time polymerase chain reaction.
RESULTS: A previously unannotated lncRNA, antihypertrophic interrelated transcript (Ahit), was identified to be upregulated in the mouse hearts after transverse aortic constriction. Inhibition of Ahit induced cardiac hypertrophy, both in vitro and in vivo, associated with increased expression of MEF2A, a critical transcriptional factor involved in cardiac hypertrophy. In contrast, overexpression of Ahit significantly attenuated stress-induced cardiac hypertrophy in vitro. Furthermore, Ahit was significantly upregulated in serum samples of patients diagnosed with hypertensive heart disease versus nonhypertrophic hearts (1.46±0.17 fold, P=0.0325). Mechanistically, Ahit directly bound and recruited SUZ12, a core PRC2 (polycomb repressive complex 2) protein, to the promoter of MEF2A, triggering its trimethylation on H3 lysine 27 (H3K27me3) residues and mediating the downregulation of MEF2A, thereby preventing cardiac hypertrophy.
CONCLUSIONS: Ahit is a lncRNA with a significant role in cardiac hypertrophy regulation through epigenomic modulation. Ahit is a potential therapeutic target of cardiac hypertrophy.

Entities:  

Keywords:  MEF2A, PRC2; RNA, long noncoding; cardiomegaly; heart failure

Mesh:

Substances:

Year:  2020        PMID: 31957467      PMCID: PMC7241255          DOI: 10.1161/CIRCHEARTFAILURE.119.006525

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  47 in total

1.  LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity.

Authors:  Gengze Wu; Jin Cai; Yu Han; Jinghai Chen; Zhan-Peng Huang; Caiyu Chen; Yue Cai; Hefei Huang; Yujia Yang; Yukai Liu; Zaicheng Xu; Duofen He; Xiaoqun Zhang; Xiaoyun Hu; Luca Pinello; Dan Zhong; Fengtian He; Guo-Cheng Yuan; Da-Zhi Wang; Chunyu Zeng
Journal:  Circulation       Date:  2014-08-25       Impact factor: 29.690

2.  Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy.

Authors:  Hee Young Seok; Jinghai Chen; Masaharu Kataoka; Zhan-Peng Huang; Jian Ding; Jinglu Yan; Xiaoyun Hu; Da-Zhi Wang
Journal:  Circ Res       Date:  2014-03-21       Impact factor: 17.367

Review 3.  Molecular mechanisms of long noncoding RNAs.

Authors:  Kevin C Wang; Howard Y Chang
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

4.  Tyrosine kinase FYN negatively regulates NOX4 in cardiac remodeling.

Authors:  Shouji Matsushima; Junya Kuroda; Peiyong Zhai; Tong Liu; Shohei Ikeda; Narayani Nagarajan; Shin-Ichi Oka; Takashi Yokota; Shintaro Kinugawa; Chiao-Po Hsu; Hong Li; Hiroyuki Tsutsui; Junichi Sadoshima
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

5.  Requirement of MEF2A, C, and D for skeletal muscle regeneration.

Authors:  Ning Liu; Benjamin R Nelson; Svetlana Bezprozvannaya; John M Shelton; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

Review 6.  EZH2 methyltransferase and H3K27 methylation in breast cancer.

Authors:  Kyung Hyun Yoo; Lothar Hennighausen
Journal:  Int J Biol Sci       Date:  2011-11-18       Impact factor: 6.580

7.  The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation.

Authors:  Felipe C Beckedorff; Ana C Ayupe; Renan Crocci-Souza; Murilo S Amaral; Helder I Nakaya; Daniela T Soltys; Carlos F M Menck; Eduardo M Reis; Sergio Verjovski-Almeida
Journal:  PLoS Genet       Date:  2013-08-22       Impact factor: 5.917

Review 8.  Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.

Authors:  Csaba András Dézsi
Journal:  Am J Cardiovasc Drugs       Date:  2014-06       Impact factor: 3.571

9.  Modular function of long noncoding RNA, COLDAIR, in the vernalization response.

Authors:  Dong-Hwan Kim; Yanpeng Xi; Sibum Sung
Journal:  PLoS Genet       Date:  2017-07-31       Impact factor: 5.917

10.  The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy.

Authors:  Zhihua Wang; Xiao-Jing Zhang; Yan-Xiao Ji; Peng Zhang; Ke-Qiong Deng; Jun Gong; Shuxun Ren; Xinghua Wang; Iris Chen; He Wang; Chen Gao; Tomohiro Yokota; Yen Sin Ang; Shen Li; Ashley Cass; Thomas M Vondriska; Guangping Li; Arjun Deb; Deepak Srivastava; Huang-Tian Yang; Xinshu Xiao; Hongliang Li; Yibin Wang
Journal:  Nat Med       Date:  2016-09-12       Impact factor: 53.440

View more
  11 in total

Review 1.  The control of polycomb repressive complexes by long noncoding RNAs.

Authors:  Jackson B Trotman; Keean C A Braceros; Rachel E Cherney; McKenzie M Murvin; J Mauro Calabrese
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-04-16       Impact factor: 9.957

2.  Weighted correlation network bioinformatics uncovers a key molecular biosignature driving the left-sided heart failure.

Authors:  Jiamin Zhou; Wei Zhang; Chunying Wei; Zhiliang Zhang; Dasong Yi; Xiaoping Peng; Jingtian Peng; Ran Yin; Zeqi Zheng; Hongmei Qi; Yunfeng Wei; Tong Wen
Journal:  BMC Med Genomics       Date:  2020-07-03       Impact factor: 3.063

Review 3.  New Insights into LINC00346 and its Role in Disease.

Authors:  Juan Lu; Zhaoying Xiao; Mengqiu Xu; Lanjuan Li
Journal:  Front Cell Dev Biol       Date:  2022-01-13

Review 4.  Multidimensional Mechanistic Spectrum of Long Non-coding RNAs in Heart Development and Disease.

Authors:  Lei Han; Lei Yang
Journal:  Front Cardiovasc Med       Date:  2021-09-16

5.  Overexpression of cytosolic long noncoding RNA cytb protects against pressure-overload-induced heart failure via sponging microRNA-103-3p.

Authors:  Xudong Zhang; Shuai Yuan; Jingbo Liu; Yuyan Tang; Yan Wang; Jiabing Zhan; Jiahui Fan; Xiang Nie; Yanru Zhao; Zheng Wen; Huaping Li; Chen Chen; Dao Wen Wang
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-10       Impact factor: 8.886

6.  Loss of m6A Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression.

Authors:  Yanchuang Han; Tailai Du; Siyao Guo; Lu Wang; Gang Dai; Tianxin Long; Ting Xu; Xiaodong Zhuang; Chen Liu; Shujuan Li; Dihua Zhang; Xinxue Liao; Yugang Dong; Kathy O Lui; Xu Tan; Shuibin Lin; Yili Chen; Zhan-Peng Huang
Journal:  Front Cardiovasc Med       Date:  2022-02-28

Review 7.  Recent advances on the roles of LncRNAs in cardiovascular disease.

Authors:  Yexian Fang; Yuerong Xu; Runze Wang; Lang Hu; Dong Guo; Feng Xue; Wangang Guo; Dongwei Zhang; Jianqiang Hu; Yan Li; Wei Zhang; Mingming Zhang
Journal:  J Cell Mol Med       Date:  2020-09-24       Impact factor: 5.310

Review 8.  LncRNAs in cardiac hypertrophy: From basic science to clinical application.

Authors:  Lei Liu; Donghui Zhang; Yifei Li
Journal:  J Cell Mol Med       Date:  2020-09-08       Impact factor: 5.310

9.  Transfection of hPSC-Cardiomyocytes Using Viafect™ Transfection Reagent.

Authors:  Sara E Bodbin; Chris Denning; Diogo Mosqueira
Journal:  Methods Protoc       Date:  2020-08-09

Review 10.  The function of LncRNA-H19 in cardiac hypertrophy.

Authors:  Wenhua Su; Qian Huo; Hao Wu; Lulin Wang; Xiaoxue Ding; Liwen Liang; Liang Zhou; Yan Zhao; Juhua Dan; Hong Zhang
Journal:  Cell Biosci       Date:  2021-08-03       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.